No Data
Xuantai Pharmaceutical: 2024 Annual Results Express Announcement
2024 Annual Results Express Announcement
Xuantai Pharmaceutical (688247.SH): Qihe and Chuangye together reduced their Shareholding by 575,200 shares.
Xuantai Pharmaceutical (688247.SH) released an announcement stating that Shareholder Qi He Chuang Ye will... on January 21, 2025.
Xuantai Pharmaceutical: 2024 Annual Results Forecast
2024 Annual Results Forecast
Xuantai Pharmaceutical (688247.SH): The net income for 2024 is expected to increase by 89% to 127%.
On January 22, Gelonghui announced that Xuantai Pharmaceutical (688247.SH) published its performance forecast for the year 2024, expecting a net income attributable to the parent company owners to be between 115.41 million yuan and 138.49 million yuan, representing a year-on-year growth of 89% to 127%. It is expected that the net income attributable to the parent company owners, excluding non-recurring gains and losses, will be between 103.2 million yuan and 123.84 million yuan, an increase of 117% to 161% compared to the same period last year. During the reporting period, the company focused on its core business and continuously strengthened domestic and international sales of its products, with the sales of major products.
